Takeda commences new study of dengue vaccine

Takeda has announced the commencement of TIDES, a phase III trial evaluating the performance of its new live-attenuated tetravalent dengue vaccine candidate TAK-003.

Approximately 20,000 healthy children between the ages of four and 16 living in dengue-endemic countries in Latin America and Asia will be enrolled in this new study, which aims to build on the success of previous phase I and II trials of the vaccine.

It will evaluate the efficacy of the vaccine in protecting subjects against symptomatic dengue fever caused by any of the four dengue virus serotypes, regardless of age and whether the individual has previously been exposed to the virus.

The study will also evaluate vaccine safety and immunogenicity, with two doses of the vaccine candidate or placebo to be administered 90 days apart.

Dr Rajeev Venkayya, president of the global vaccine business unit at Takeda, said: "This is a significant achievement for Takeda's vaccine programme and underscores our ongoing commitment to addressing critical global health threats."

In earlier studies, TAK-003 induced neutralising antibody responses against all four dengue virus serotypes across multiple age groups and in both seropositive and seronegative individuals, with no observed safety concerns.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.